РАЗРАБОТКА И ПОЛУЧЕНИЕ ДНК-ИММУНОГЕНА НА ОСНОВЕ ГЕНОВ SARS-COV-2

1. Dey, A. (2021) Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV 2 in animal models. Vaccine, 39(30), 4108-4116.

2. Dhanda, S.K. (2018) Prediction of HLA CD4 immunogenicity in human populations. Front. Immunol., 9, 1369.

3. Dukhovlinov, I.V., Chirak, E.L., Kolmakov, N.N., Fedorova, E.A. and Alekseev, A.V., (2020) Pat. of the Russian Federation № 2747762, PCT/RU2020/000257 appl. 5.04.2020

4. He, Q. (2004) Development of a Western Blot Assay for Detection of Antibodies against Coronavirus Causing Severe Acute Respiratory Syndrome. Clin. Diagn. Lab. Immunol., 11(2), 417-422.

5. Lee, J. (2018) Engineering DNA vaccines against infectious diseases. Acta Biomater., 80, 31-47.

6. Momin, Т. (2021) Safety and Immunogenicity of a DNA SARS-CoV 2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India. EClinicalMedicine, 38.

7. Rodrigues, João P.G.L.M. (2020) Insights on cross-species transmission of SARS-CoV 2 from structural modeling. PLoS Comput Biol., 16(12).

8. Vojdania, A., Kharrazianb, D. (2020) Potential antigenic cross-reactivity between SARS-CoV 2 and human tissue with a possible link to an increase in autoimmune diseases. Clinical Immunology, 217, 1-2.

9. Williams, J.A. (2010) Generic plasmid DNA production platform incorporating low metabolic burden seed-stock and fed-batch fermentation processes. Biotechnol Bioeng., 103(6), 1129-1143.

10. Zhao, J. (2020) Antibody responses to SARS-CoV 2 in patients of novel Antibody responses to SARS-CoV 2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis, 71(16), 2027-2034.